Chiauranib
Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.
Overview
Chiauranib (CS2164) is a small-molecule drug developed by Chipscreen Biosciences. Its targets are VEGF / VEGFR, KIT, PDGFRA, CSF1R and Folate receptor alpha (the sponsor names VEGFR1, VEGFR2, VEGFR3, PDGFRa, c-Kit, Aurora B, CSF-1R). The sponsor states: A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04921527 (Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer), in ovarian cancer. The largest, NCT04921527, plans to enrol 454 participants with primary completion expected 2024-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Chiauranib" OR ABSTRACT:"Chiauranib" OR TITLE:"CS2164" OR ABSTRACT:"CS2164") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Chiauranib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentSofetabart Mipitecan
Shares Folate receptor alpha, Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentFarletuzumab-exatecan
Shares Folate receptor alpha and the tags pipeline, ctgov-ingest.
- TreatmentEmactuzumab
Shares CSF1R and the tags pipeline, ctgov-ingest.
- TreatmentAI-081
Shares VEGF / VEGFR and the tags pipeline, ctgov-ingest.
- TreatmentBezuclastinib
Shares KIT and the tags pipeline, ctgov-ingest.
- TreatmentAL2846
Shares KIT and the tags pipeline, ctgov-ingest.
- TreatmentTovecimig
Shares VEGF / VEGFR and the tags pipeline, ctgov-ingest.
- TreatmentIMP4927
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.